Drug intelligence / Profile preview

GCC-CART

Development stage: Unknown
Lead developer: Lyell Immunopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GCC-CART is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting Guanylyl Cyclase C (GUCY2C), a transmembrane receptor primarily expressed on the apical surface of intestinal epithelial cells and frequently overexpressed in metastatic colorectal cancer (mCRC). Developed by Protheragen, the therapy involves engineering a patient's T cells to express a CAR specific to GUCY2C, enabling the cells to recognize and eliminate GUCY2C-positive tumor cells. The program is currently in Phase I clinical development for the treatment of metastatic colorectal cancer.

Other names: GUCY2C CAR-TGUCY-2C CAR-TGUCY 2C CAR-TGCC CAR-T

Targets

GUCY2C (Guanylate cyclase C receptor)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on GCC-CART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCC-CART.

Explore the full profile